![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: PLAU |
Gene summary for PLAU |
![]() |
Gene information | Species | Human | Gene symbol | PLAU | Gene ID | 5328 |
Gene name | plasminogen activator, urokinase | |
Gene Alias | ATF | |
Cytomap | 10q22.2 | |
Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | P00749 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
5328 | PLAU | CA_HPV_2 | Human | Cervix | CC | 3.31e-04 | 3.27e-01 | 0.0391 |
5328 | PLAU | Tumor | Human | Cervix | CC | 6.94e-09 | 3.60e-01 | 0.1241 |
5328 | PLAU | sample1 | Human | Cervix | CC | 4.14e-02 | 3.83e-01 | 0.0959 |
5328 | PLAU | sample3 | Human | Cervix | CC | 3.87e-25 | 6.78e-01 | 0.1387 |
5328 | PLAU | T1 | Human | Cervix | CC | 4.46e-04 | 3.39e-01 | 0.0918 |
5328 | PLAU | T3 | Human | Cervix | CC | 1.45e-23 | 6.42e-01 | 0.1389 |
5328 | PLAU | LZE4T | Human | Esophagus | ESCC | 8.88e-10 | 6.09e-01 | 0.0811 |
5328 | PLAU | LZE8T | Human | Esophagus | ESCC | 7.28e-17 | 1.34e+00 | 0.067 |
5328 | PLAU | LZE20T | Human | Esophagus | ESCC | 4.67e-04 | 4.20e-01 | 0.0662 |
5328 | PLAU | LZE22T | Human | Esophagus | ESCC | 2.81e-04 | 1.06e+00 | 0.068 |
5328 | PLAU | LZE24T | Human | Esophagus | ESCC | 1.83e-07 | 1.77e+00 | 0.0596 |
5328 | PLAU | LZE21T | Human | Esophagus | ESCC | 9.81e-09 | 7.97e-01 | 0.0655 |
5328 | PLAU | P1T-E | Human | Esophagus | ESCC | 9.89e-06 | 1.90e+00 | 0.0875 |
5328 | PLAU | P2T-E | Human | Esophagus | ESCC | 6.06e-38 | 1.54e+00 | 0.1177 |
5328 | PLAU | P4T-E | Human | Esophagus | ESCC | 5.05e-52 | 2.16e+00 | 0.1323 |
5328 | PLAU | P5T-E | Human | Esophagus | ESCC | 1.80e-29 | 1.03e+00 | 0.1327 |
5328 | PLAU | P9T-E | Human | Esophagus | ESCC | 6.08e-10 | 4.89e-01 | 0.1131 |
5328 | PLAU | P11T-E | Human | Esophagus | ESCC | 1.17e-24 | 3.12e+00 | 0.1426 |
5328 | PLAU | P12T-E | Human | Esophagus | ESCC | 3.26e-19 | 6.73e-01 | 0.1122 |
5328 | PLAU | P15T-E | Human | Esophagus | ESCC | 7.98e-22 | 7.97e-01 | 0.1149 |
Page: 1 2 3 4 5 6 7 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00971939 | Breast | Precancer | intrinsic apoptotic signaling pathway | 59/1080 | 288/18723 | 8.07e-18 | 3.60e-15 | 59 |
GO:20012339 | Breast | Precancer | regulation of apoptotic signaling pathway | 65/1080 | 356/18723 | 7.70e-17 | 3.17e-14 | 65 |
GO:20012429 | Breast | Precancer | regulation of intrinsic apoptotic signaling pathway | 41/1080 | 164/18723 | 6.48e-16 | 2.31e-13 | 41 |
GO:00525479 | Breast | Precancer | regulation of peptidase activity | 71/1080 | 461/18723 | 2.72e-14 | 6.94e-12 | 71 |
GO:00525489 | Breast | Precancer | regulation of endopeptidase activity | 67/1080 | 432/18723 | 1.06e-13 | 2.36e-11 | 67 |
GO:20001169 | Breast | Precancer | regulation of cysteine-type endopeptidase activity | 43/1080 | 235/18723 | 1.30e-11 | 1.83e-09 | 43 |
GO:00432819 | Breast | Precancer | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 40/1080 | 209/18723 | 1.59e-11 | 2.07e-09 | 40 |
GO:20012349 | Breast | Precancer | negative regulation of apoptotic signaling pathway | 39/1080 | 224/18723 | 5.35e-10 | 4.77e-08 | 39 |
GO:00458619 | Breast | Precancer | negative regulation of proteolysis | 50/1080 | 351/18723 | 2.99e-09 | 2.39e-07 | 50 |
GO:20012439 | Breast | Precancer | negative regulation of intrinsic apoptotic signaling pathway | 23/1080 | 98/18723 | 5.82e-09 | 4.45e-07 | 23 |
GO:00086378 | Breast | Precancer | apoptotic mitochondrial changes | 23/1080 | 107/18723 | 3.44e-08 | 2.12e-06 | 23 |
GO:00513468 | Breast | Precancer | negative regulation of hydrolase activity | 50/1080 | 379/18723 | 3.85e-08 | 2.34e-06 | 50 |
GO:00104668 | Breast | Precancer | negative regulation of peptidase activity | 38/1080 | 262/18723 | 1.46e-07 | 7.82e-06 | 38 |
GO:00109519 | Breast | Precancer | negative regulation of endopeptidase activity | 37/1080 | 252/18723 | 1.55e-07 | 8.05e-06 | 37 |
GO:20001179 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity | 19/1080 | 86/18723 | 3.36e-07 | 1.58e-05 | 19 |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00511019 | Breast | Precancer | regulation of DNA binding | 22/1080 | 118/18723 | 9.28e-07 | 3.71e-05 | 22 |
GO:00431548 | Breast | Precancer | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process | 17/1080 | 78/18723 | 1.69e-06 | 6.08e-05 | 17 |
GO:00433887 | Breast | Precancer | positive regulation of DNA binding | 14/1080 | 56/18723 | 2.46e-06 | 8.35e-05 | 14 |
GO:00510989 | Breast | Precancer | regulation of binding | 44/1080 | 363/18723 | 2.59e-06 | 8.65e-05 | 44 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0521512 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0521516 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa040645 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa052028 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0521517 | Esophagus | ESCC | Prostate cancer | 72/4205 | 97/8465 | 6.12e-07 | 4.10e-06 | 2.10e-06 | 72 |
hsa0406412 | Esophagus | ESCC | NF-kappa B signaling pathway | 67/4205 | 104/8465 | 1.62e-03 | 4.89e-03 | 2.50e-03 | 67 |
hsa0520213 | Esophagus | ESCC | Transcriptional misregulation in cancer | 116/4205 | 193/8465 | 2.08e-03 | 5.95e-03 | 3.05e-03 | 116 |
hsa0520526 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0521510 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa040644 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa05205111 | Oral cavity | OSCC | Proteoglycans in cancer | 128/3704 | 205/8465 | 4.00e-08 | 3.12e-07 | 1.59e-07 | 128 |
hsa0521515 | Oral cavity | OSCC | Prostate cancer | 66/3704 | 97/8465 | 1.05e-06 | 5.89e-06 | 3.00e-06 | 66 |
hsa0406411 | Oral cavity | OSCC | NF-kappa B signaling pathway | 67/3704 | 104/8465 | 1.57e-05 | 6.75e-05 | 3.44e-05 | 67 |
hsa0520527 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
hsa0520536 | Oral cavity | LP | Proteoglycans in cancer | 77/2418 | 205/8465 | 3.01e-03 | 1.29e-02 | 8.35e-03 | 77 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLAU | SNV | Missense_Mutation | novel | c.797G>A | p.Ser266Asn | p.S266N | P00749 | protein_coding | tolerated(0.17) | benign(0.007) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAU | SNV | Missense_Mutation | novel | c.457G>T | p.Asp153Tyr | p.D153Y | P00749 | protein_coding | tolerated(1) | benign(0.098) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAU | SNV | Missense_Mutation | novel | c.1108G>T | p.Asp370Tyr | p.D370Y | P00749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAU | SNV | Missense_Mutation | rs146899371 | c.973N>A | p.Asp325Asn | p.D325N | P00749 | protein_coding | deleterious(0.04) | probably_damaging(0.92) | TCGA-EY-A549-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAU | SNV | Missense_Mutation | novel | c.248G>A | p.Ser83Asn | p.S83N | P00749 | protein_coding | tolerated(0.88) | benign(0.001) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
PLAU | SNV | Missense_Mutation | novel | c.395N>T | p.Trp132Leu | p.W132L | P00749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-2Y-A9GU-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAU | SNV | Missense_Mutation | novel | c.161C>A | p.Pro54Gln | p.P54Q | P00749 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-05-4396-01 | Lung | lung adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
PLAU | SNV | Missense_Mutation | c.398N>T | p.Cys133Phe | p.C133F | P00749 | protein_coding | deleterious(0) | probably_damaging(0.914) | TCGA-44-3918-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
PLAU | SNV | Missense_Mutation | c.1093N>A | p.Pro365Thr | p.P365T | P00749 | protein_coding | tolerated(0.15) | possibly_damaging(0.892) | TCGA-55-8616-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
PLAU | SNV | Missense_Mutation | c.863G>A | p.Cys288Tyr | p.C288Y | P00749 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-62-A46P-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | RETINOL | RETINOL | 1576255 | |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | ALENDRONATE | ALENDRONIC ACID | 11984068 | |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | RAZOXANE | RAZOXANE | 9378540 | |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | MRX-801 | |||
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | BCNU | CARMUSTINE | 9219734 | |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | DIFFERENTIATION INDUCER | 8595156 | ||
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | CORTISOL | HYDROCORTISONE | 2115769 | |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | G-CSF | FILGRASTIM | 16331631 | |
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | ANTIOXIDANT | 9573532 | ||
5328 | PLAU | PROTEASE, DRUGGABLE GENOME, ENZYME, CELL SURFACE | CALCITRIOL | CALCITRIOL | 3139763 |
Page: 1 2 3 4 5 6 |